ETON

#2103
Eton Pharmaceuticals, Inc. - Common Stock
59.9 0 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
59.90
59.90
Jahresspanne
14.27
66.37
Tagesänderung
-3.32%
Monatliche Änderung
+24.87%
6 month change
+241.70%
Jahresänderung
+231.31%
Vorheriger Schlusskurs
61.9 6
Open
59.9 0
Tief
59.9 0
Hoch
59.9 0
Volumen
163
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Eton Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Eton Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Eton Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Eton Pharmaceuticals, Inc. current report, Q1 FY2026

Full document

Eton Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

Eton Pharmaceuticals, Inc. (NASDAQ: ETON) filed this Current Report on Form 8-K on March 19, 2026. The filing serves to announce the company's financial results for the fourth quarter and the twelve months ended December 31, 2025. The full details of these results are contained in a press release attached as Exhibit 99.1.

Key Financial Metrics

The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document references the use of "Adjusted EBITDA" as a non-GAAP financial measure to evaluate operating performance but does not disclose the actual calculated figures within this text.

Material Changes

The filing text does not provide specific data regarding material changes in financial performance compared to prior periods. It notes that management uses Adjusted EBITDA to compare performance across reporting periods by excluding items not indicative of core operating performance, but no comparative historical data is included in this excerpt.

Guidance, Outlook, and Management Commentary

Management commentary focuses on the utility of Adjusted EBITDA for internal planning, budget preparation, and evaluating business strategies. The company states that this metric assists in communicating financial performance to the board and investors. No specific forward-looking guidance, risk factors, or contingencies are detailed in the provided text beyond the standard disclosure that the information is furnished and not deemed "filed" under Section 18 of the Exchange Act.

Investor Verification Checklist

  • Review Exhibit 99.1 (the attached Press Release) for specific revenue, net income, and cash flow figures for Q4 and FY 2025.
  • Verify the reconciliation between GAAP net income and the non-GAAP Adjusted EBITDA metric mentioned in the filing.
  • Confirm the specific adjustments made to arrive at Adjusted EBITDA to understand the impact of excluded items.
  • Check for any updated forward-looking guidance or operational milestones in the full press release.

Nachrichten